The injectable GLP-1 medications currently on the market have published higher average weight loss figures in their landmark trials: Semaglutide (Wegovy): Demonstrated approximately 14.9% average body weight reduction in the STEP 1 trial
The metabolic consequences of obesityparticularly insulin resistance, hypothalamic dysfunction, and impaired mitochondrial metabolismare increasingly recognized as playing central roles in migraine pathophysiology
Louis , we understand that sustainable weight loss is not one-size-fits-all
The study found that those taking the highest dose lost an average of about 30% of their body weight, or about 85 lbs
Complementing these findings, a separate trial assessing the efficacy of exenatide for alcohol use disorder also showed no significant difference in heavy drinking days overall
Clinical trials have demonstrated substantial reductions in hemoglobin A1c levels (up to 2.5% reduction) in type 2 diabetes, while weight management trials showed 15-21% weight loss in adults with obesity without diabetes
